Major PBMs Inflated Drug Prices, Pocketing $7.3 Billion Along the Way, FTC Says
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of acquisition, earning more than $7.3 billion in revenue from 2017 to 2022, according to a report issued by the Federal Trade Commission (FTC) on Tuesday.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
In the debate over the high cost of prescription drugs, pharmacy benefit managers are hotly contested. PBMs, the middlemen in ...
Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...
The Arkansas Pharmacists Association is calling for public and legislative support for stronger regulation of Pharmacy ...
The Federal Trade Commission published a second interim staff report this week on the prescription drug middleman industry, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback